NCT05276830View on ClinicalTrials.gov

An Efficacy, and Safety Study Of BXCL501 For The Treatment Of Agitation Associated With Dementia

PHASE2TerminatedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

February 8, 2022

Primary Completion Date

April 1, 2022

Study Completion Date

April 1, 2022

Conditions
AgitationDementia
Interventions
DRUG

BXCL501

Sublingual film containing 40 Micrograms BXCL501

DRUG

BXCL501

Sublingual film containing 60 Micrograms BXCL501

DRUG

Placebo film

Matching Sublingual Placebo film

Trial Locations (3)

33161

Bioxcel Clinical Research Site, North Miami

01103

Bioxcel Clinical Research Site, Springfield

08755

BioXcel Clinical Research Site, Toms River

Sponsors
All Listed Sponsors
collaborator

Cognitive Research Corporation

INDUSTRY

lead

BioXcel Therapeutics Inc

INDUSTRY